isoniazid has been researched along with triclosan in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.33) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 6 (20.00) | 29.6817 |
| 2010's | 17 (56.67) | 24.3611 |
| 2020's | 5 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, JW; Fidock, DA; Freundlich, JS; Jacobs, WR; Jacobus, DP; Kumar, TR; Kuo, M; Nkrumah, LJ; Sacchettini, JC; Schiehser, GA; Shieh, HM; Tsai, HC; Valderramos, JC; Valderramos, SG; Wang, F; Yu, M | 1 |
| Bhat, AR; Bryant, B; Dayan, FE; Kini, SG; Williamson, JS | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bernadou, J; Bernardes-Génisson, V; Constant, P; Deraeve, C; Dorobantu, IM; Le Quéméner, F; Pratviel, G; Quémard, A; Rebbah, F | 1 |
| Bairwa, VK; Bellubi, A; Satardekar, K; Telvekar, VN | 1 |
| Baltas, M; Frongia, C; Lherbet, C; Lobjois, V; Menendez, C; Pasca, MR; Ribeiro, AL; Rodriguez, F; Saffon, N; Zara, F | 1 |
| Ambady, A; Bandodkar, B; Bhat, J; Davies, G; Hameed, S; Hegde, N; Holdgate, G; Kumar, A; Madhavapeddi, P; McMiken, H; Murugan, K; Naik, M; Nandishaiah, R; Panda, M; Read, JA; Sambandamurthy, VK; Shinde, V; Shirude, PS; Venkatraman, J | 1 |
| Baltas, M; Gorichko, M; Guidetti, B; Lherbet, C; Matviiuk, T; Mori, G; Pasca, MR; Rodriguez, F; Voitenko, Z | 1 |
| Aminabhavi, TM; Gadad, AK; Joshi, SD; Kulkarni, VH; More, UA; Nadagouda, MN | 1 |
| Achar, V; Ambady, A; Awasthy, D; Bandodkar, B; Bellale, E; Chatterji, M; Guptha, S; Kaur, P; McLaughlin, R; Morayya, S; Naik, M; Narayan, A; Panda, M; Raichurkar, A; Ramachandran, V; Ravishankar, S; Sharma, S; V B, V; Vachaspati, P; Whiteaker, J | 1 |
| Balakrishnan, G; Bhat, J; Chatterji, M; Dinesh, N; Ghorpade, S; Gorai, G; Guptha, S; Humnabadkar, V; Iyer, PS; Jena, LK; Kaur, P; Khadtare, P; Naik, M; Nandishaiah, R; Narayan, A; Naviri, LK; Panda, M; Ramachandran, V; Sharma, S | 1 |
| Aminabhavi, TM; Badiger, AM; Joshi, SD; Kulkarni, VH; Lherbet, C; More, UA | 1 |
| Aoki, S; Gulten, G; Kanetaka, H; Kitamura, M; Komatsu, H; Koseki, Y; Sacchettini, JC; Sakamoto, H; Taira, J; Umei, T | 1 |
| Aminabhavi, TM; Dixit, SR; Joshi, SD; Kumar, D; Lherbet, C; More, UA; Tigadi, N; Yang, KS | 1 |
| Bernardes-Génisson, V; Chollet, A; Lherbet, C; Maveyraud, L | 1 |
| Duan, YT; Lv, PC; Wang, TT; Wang, XM; Xu, JF; Xu, YJ; Yang, YS; Yuan, Q; Zhu, HL | 1 |
| Doğan, H; Doğan, ŞD; Gündüz, MG; Krishna, VS; Lherbet, C; Şahin, O; Sarıpınar, E; Sriram, D | 1 |
| Abell, C; Blundell, TL; Coyne, AG; Dias, DMG; Korduláková, J; Mendes, V; Mikušová, K; Sabbah, M; Vistal, RG; Záhorszká, M | 1 |
| Doğan, H; Doğan, ŞD; Gündüz, MG; Krishna, VS; Lherbet, C; Sriram, D | 1 |
| Baulard, AR; Biela, A; Blaise, M; Bourbiaux, K; Cantrelle, FX; Déprez, B; Djaout, K; Faïon, L; Flipo, M; Frita, R; Hanoulle, X; Herledan, A; Kremer, L; Leroux, F; Moune, M; Pintiala, C; Piveteau, C; Tanina, A; Vandeputte, A; Willand, N; Wintjens, R | 1 |
| Levy, SB; McDermott, PF; McMurry, LM | 1 |
| Parikh, SL; Tonge, PJ; Xiao, G | 1 |
| Barry, CE; Lee, RE; Slayden, RA | 1 |
| Barry, CE; Slayden, RA | 1 |
| Betts, JC; Blakemore, SJ; Duncan, K; Kelly, FM; Lennon, MG; Lukey, PT; McLaren, A | 1 |
| HIGUCHI, T; REINSTEIN, JA | 1 |
| Chen, YD; Lu, XY; You, QD | 1 |
| Cheng, YR; Cui, GZ; Cui, Q; Song, X; Sun, ZJ | 1 |
| Dutta, D; Kumar Das, A; Kundu, P | 1 |
| Campos, AR; Fraz, S; Lee, AH; Purohit, U; Wilson, JY | 1 |
2 review(s) available for isoniazid and triclosan
| Article | Year |
|---|---|
An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors.
Topics: Bacterial Proteins; Biological Products; Crystallography, X-Ray; Dose-Response Relationship, Drug; Ligands; Models, Molecular; Molecular Structure; Oxidoreductases; Structure-Activity Relationship | 2018 |
Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Enzyme Inhibitors; Isoniazid; Mycobacterium tuberculosis; NAD; Oxidoreductases; Pyrazoles; Triclosan | 2010 |
28 other study(ies) available for isoniazid and triclosan
| Article | Year |
|---|---|
X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy.
Topics: Animals; Antimalarials; Binding Sites; Crystallography, X-Ray; Drug Design; Drug Resistance; Models, Molecular; Oxidoreductases Acting on CH-CH Group Donors; Plasmodium falciparum; Protein Structure, Tertiary; Protozoan Proteins; Triclosan | 2007 |
Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives.
Topics: Antitubercular Agents; Azoles; Binding Sites; Computer Simulation; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Humans; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium; Phenyl Ethers; Protein Binding | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Chemical synthesis, biological evaluation and structure-activity relationship analysis of azaisoindolinones, a novel class of direct enoyl-ACP reductase inhibitors as potential antimycobacterial agents.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cell Line; Enzyme Inhibitors; Humans; Indoles; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Oxidoreductases; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Infrared; Structure-Activity Relationship | 2011 |
Novel 2-(2-(4-aryloxybenzylidene) hydrazinyl)benzothiazole derivatives as anti-tubercular agents.
Topics: Antitubercular Agents; Benzothiazoles; Chemistry, Pharmaceutical; Drug Design; Escherichia coli; Humans; Hydrazines; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microbial Sensitivity Tests; Models, Chemical; Mycobacterium; Mycobacterium tuberculosis; Spectrophotometry, Infrared; Structure-Activity Relationship; Tuberculosis | 2012 |
Synthesis and evaluation of α-ketotriazoles and α,β-diketotriazoles as inhibitors of Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; HCT116 Cells; Humans; Ketones; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Triazoles | 2013 |
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
Topics: Bacterial Proteins; Crystallography, X-Ray; Dose-Response Relationship, Drug; Enzyme Inhibitors; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Oxidoreductases; Structure-Activity Relationship; Thiazoles | 2013 |
Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Humans; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium tuberculosis; Oxidoreductases; Pyrrolidines; Structure-Activity Relationship; Tuberculosis | 2014 |
Design, synthesis, molecular docking and 3D-QSAR studies of potent inhibitors of enoyl-acyl carrier protein reductase as potential antimycobacterial agents.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Drug Design; Humans; Hydrazones; Ligands; Molecular Docking Simulation; Mycobacterium tuberculosis; Oxidoreductases; Pyrroles; Quantitative Structure-Activity Relationship; Tuberculosis | 2014 |
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; High-Throughput Screening Assays; Humans; Mice; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Polymorphism, Single Nucleotide; Protein Kinases; Small Molecule Libraries; Structure-Activity Relationship; Thiazoles | 2014 |
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
Topics: | 2014 |
Discovery of target based novel pyrrolyl phenoxy derivatives as antimycobacterial agents: an in silico approach.
Topics: Anti-Bacterial Agents; Computer Simulation; Dose-Response Relationship, Drug; Drug Discovery; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Structure-Activity Relationship | 2015 |
Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Cell Line; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Mycobacterium smegmatis; Oxidoreductases; Structure-Activity Relationship | 2015 |
Synthesis, characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes.
Topics: A549 Cells; Anti-Bacterial Agents; Antitubercular Agents; Cells; Coordination Complexes; Copper; Humans; Hydrazones; Ligands; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Quantitative Structure-Activity Relationship | 2016 |
Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
Topics: Antitubercular Agents; Bacterial Proteins; Binding Sites; Drug Evaluation, Preclinical; Isoniazid; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Oxidoreductases; Protein Structure, Tertiary; Quantitative Structure-Activity Relationship; Rhodanine | 2019 |
Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Hydrazones; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Oxidoreductases; RAW 264.7 Cells; Structure-Activity Relationship; Thiadiazoles | 2020 |
Fragment-Based Design of
Topics: Antitubercular Agents; Bacterial Proteins; Binding Sites; Drug Design; Enzyme Assays; Enzyme Inhibitors; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Oxidoreductases; Protein Binding; Small Molecule Libraries; Structure-Activity Relationship; Sulfonamides | 2020 |
Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Oxidoreductases; RAW 264.7 Cells; Structure-Activity Relationship; Thiourea | 2020 |
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening.
Topics: Bacterial Proteins; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fatty Acid Synthases; Molecular Structure; Mycobacterium tuberculosis; ortho-Aminobenzoates; Structure-Activity Relationship | 2020 |
Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan.
Topics: Anti-Infective Agents, Local; Bacterial Proteins; Humans; Isoniazid; Mutation; Mycobacterium smegmatis; Oxidoreductases; Triclosan | 1999 |
Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
Topics: Antitubercular Agents; Bacterial Proteins; Binding Sites; Drug Resistance, Microbial; Enzyme Inhibitors; Isoniazid; Kinetics; Mutation; Mycobacterium tuberculosis; Oxidoreductases; Triclosan | 2000 |
Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.
Topics: 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase; Acetyltransferases; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Enzyme Inhibitors; Fatty Acid Synthase, Type II; Humans; Isoniazid; Lipids; Microbial Sensitivity Tests; Multienzyme Complexes; Mycobacterium smegmatis; Mycobacterium tuberculosis; Operon; Oxidoreductases; Thiophenes; Triclosan | 2000 |
The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis.
Topics: 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase; Antibiotics, Antitubercular; Cell-Free System; Culture Media; Drug Resistance, Bacterial; Fatty Acid Synthases; Isoniazid; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Mycolic Acids; Substrate Specificity; Thiophenes; Triclosan | 2002 |
Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Local; Antitubercular Agents; DNA, Complementary; Down-Regulation; Gene Expression Regulation, Bacterial; Isoniazid; Mycobacterium tuberculosis; Oligonucleotide Array Sequence Analysis; Operon; Reverse Transcriptase Polymerase Chain Reaction; RNA, Bacterial; Thiophenes; Triclosan; Up-Regulation | 2003 |
Examination of the physical chemical basis for the isoniazid-p-aminosalicylic acid combination.
Topics: Aminosalicylic Acids; Isoniazid; Physical Examination; Triclosan | 1958 |
A new strategy for strain improvement of Aurantiochytrium sp. based on heavy-ions mutagenesis and synergistic effects of cold stress and inhibitors of enoyl-ACP reductase.
Topics: Cold Temperature; Dietary Supplements; Docosahexaenoic Acids; Enoyl-(Acyl-Carrier Protein) Reductase (NADPH, B-Specific); Enzyme Inhibitors; Fatty Acid Synthase, Type II; Fermentation; Ions; Isoniazid; Mutagenesis; Stramenopiles; Stress, Physiological; Triclosan | 2016 |
The α1β1 region is crucial for biofilm enhancement activity of MTC28 in Mycobacterium smegmatis.
Topics: Amino Acid Sequence; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Biofilms; Cell Wall; Cloning, Molecular; Drug Resistance, Bacterial; Escherichia coli; Gene Expression; Hydrophobic and Hydrophilic Interactions; Isoniazid; Kinetics; Models, Molecular; Mycobacterium smegmatis; Mycobacterium tuberculosis; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Recombinant Proteins; Sequence Alignment; Structure-Activity Relationship; Triclosan | 2017 |
Chronic exposure of Brown (Hydra oligactis) and green Hydra (Hydra viridissima) to environmentally relevant concentrations of pharmaceuticals.
Topics: Animals; Carbamazepine; Fresh Water; Hydra; Toxicity Tests; Triclosan | 2020 |